BRISBANE, Calif., June 21, 2019 /PRNewswire/ — Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced the upcoming presentation of data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. The initial results of the study will be reported in an oral presentation at the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH), in Melbourne, Australia, July 6-10, 2019. SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer.

Share this story, choose your platform!